_256_384.jpg)
Drug Approval | April 14, 2024
Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations
This facility manufactures APIs & formulations of oncology and non-oncology products.
This facility manufactures APIs & formulations of oncology and non-oncology products.
Sun Pharma's Dadra facility receives OAI status from US FDA
The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac Tablets of Eli Lilly
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
The observations are procedural in nature and will be responded to within the stipulated time
A game changing solution for the pharmaceutical industry
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
Subscribe To Our Newsletter & Stay Updated
